Immunomedics in $2 billion licensing deal with Seattle Genetics

Immunomedics in $2 billion licensing deal with Seattle Genetics


Immunomedics Inc said it entered into a licensing deal for its cancer treatment with Seattle Genetics Inc for a potential payment of up to about $2 billion. U.S. Democrat Senator Claire McCaskill on Thursday asked Kaleo Pharmaceuticals to justify the more than 550 percent surge in the price of its device to treat painkiller overdoses, becoming the second senator to question Evzio's $4,500 price tag.



from Biotech News